NFKB1 and Alzheimer disease: Previous studies have shown that intravenous injection of OXT, which specifically binds to pathologically upregulated OXTR, can reduce the levels of inflammatory cytokines and alleviate AD pathological damage by blocking the ERK/p38 MAPK and COX‐2/iNOS NF‐κB signaling pathways [46].